Vyome Reports Preclinical Data for Topical Mycophenolate

Vyome Holdings has presented new preclinical data for VT-1908, the first-ever topical mycophenolate eye drop formulated to treat uveitis, at the Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics.

Exploring Alternatives to Steroid-Based Uveitis Treatments

While steroids remain the standard first-line treatment for uveitis, their long-term use is associated with serious complications such as cataract formation and increased intraocular pressure (IOP), which can lead to glaucoma. Furthermore, a significant portion of patients are either unresponsive to steroids or experience intolerable side effects.

Vyome’s investigational candidate, VT-1908, aims to address this clinical gap by offering a topically administered, non-steroidal anti-inflammatory therapy. Mycophenolate, the active agent in VT-1908, is an established systemic immunosuppressant, but has never been previously formulated as an ophthalmic eye drop.

Key Preclinical Findings

In a preclinical anterior uveitis model, a validated simulation of the most common clinical form of the disease, twice-daily administration of VT-1908 demonstrated the following:

• Significant reduction in uveitis scores, indicating potent anti-inflammatory activity

• Comparable efficacy to a clinically used steroid, suggesting its potential as a steroid-sparing alternative

“These early observations suggest VT-1953 is meeting the clinical benchmarks to advance further in clinical trials and offer hope that a breakthrough treatment is potentially on the horizon for patients with MFW,” said Dr. Shiladitya Sengupta, Vyome co-founder and Associate Professor of Medicine at Harvard Medical School.

Clinical Development Plans and Market Outlook

Venkat Nelabhotla, CEO of Vyome Holdings, shared that a Phase 1/2 clinical trial of VT-1908 is scheduled to begin in the second half of 2026, initially targeting uveitis. The company plans to expand the indication to a broader range of ocular inflammatory conditions over time. Vyome aims to position VT-1908 as a steroid replacement therapy, addressing a global market opportunity projected to exceed $20 billion.